Related Experiment Video
Updated: Aug 6, 2026

04:53
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Home parenteral lipids in AIDS: a three-month study
P Singer1, R Levine, M Rothkopf
1General Intensive Care Unit, Beilinson Medical Center, Petah Tiqva, Israel.
Nutrition (Burbank, Los Angeles County, Calif.)
|February 1, 1997
Summary
Parenteral nutrition improved weight and activity in AIDS patients. High phospholipid formulations trapped cholesterol but did not enhance immune function or affect HIV infectivity.
Area of Science:
- Nutrition and Immunology
- Biochemistry
Background:
- Parenteral nutrition (PN) is crucial for AIDS patients with wasting syndrome and GI dysfunction.
- Human immunodeficiency virus (HIV) membranes exhibit high cholesterol (CHOL) levels.
- Lipid formulations with high phospholipid (PL) content can modify cell membrane composition by trapping CHOL.
Purpose of the Study:
- To evaluate the impact of lipid-based home parenteral nutrition on malnourished AIDS patients.
- To compare a standard 20% fat emulsion PN with a 2% formulation enriched 10-fold with PLs.
Main Methods:
- Malnourished AIDS patients received either regular or high-PL PN for 3 months.
- Patients were randomly assigned to two groups: regular 20% fat emulsion (n=23) or high-PL 2% formulation (n=27).
- Nutritional status, immune markers (CD4 cells, IgA), and HIV infectivity were assessed.
Main Results:
- Both groups showed weight gain and improved activity levels.
- The high-PL group had increased serum CHOL (147 to 241 mg/dL; P < 0.01) but no change in CD4 cells or immune function.
- Standard PL formulation decreased IgA (776 to 300 mg/dL; P < 0.02) and improved mitogen response.
Conclusions:
- Standard parenteral nutrition positively influences the nutritional and immune status of malnourished AIDS patients.
- A PL-enriched PN formulation effectively traps CHOL but does not improve immune profile or affect HIV infectivity in advanced disease.

